3005 – ELIMINATION OF RUNX1 MUTANT PRE-LEUKEMIC CLONES IN THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Sign Up to like & getrecommendations! Published in 2020 at "Experimental Hematology"
DOI: 10.1016/j.exphem.2020.09.027
Abstract: Therapy-related Myelodysplastic Syndrome (t-MDS) accounts for up to 20% of all MDS cases and its prevalence is expected to grow as more cancer patients survive. Unfortunately, the prognosis for t-MDS remains poor with 5-year overall… read more here.
Keywords: related myelodysplastic; elimination runx1; 3005 elimination; myelodysplastic syndrome ... See more keywords